SCHEMBL3281262

SCHEMBL3281262

CC1CCN(C(=O)CNC(=O)c2ccc(S(=O)(=O)Nc3ccccc3C(=O)c3ccccc3)cc2)CC1

nearest known ligand 0.50

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
BDKRB1 P46663 12/20 0.50
SMN1; SMN2 Q16637 1/20 0.49
THRA P10827 1/20 0.49
THRB P10828 1/20 0.49
ALDH1A1 P00352 2/20 0.48
KCNH2 Q12809 2/20 0.47
CYP1A2 P05177 1/20 0.45
HPGD P15428 1/20 0.45
HSD17B10 Q99714 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3281648 0.92 SMN1; SMN2 (0.50) BDKRB1SMN1; SMN2THRAALDH1A1KCNH2
SCHEMBL15103872 0.91 SMN1; SMN2 (0.54) BDKRB1SMN1; SMN2ALDH1A1KCNH2CYP1A2
Hydrochloric Acid SCHEMBL3277445 0.90 SMN1; SMN2 (0.51) BDKRB1SMN1; SMN2THRAALDH1A1KCNH2
SCHEMBL3274343 0.90 SMN1; SMN2 (0.48) BDKRB1SMN1; SMN2KCNH2
SCHEMBL15103982 0.89 BDKRB1 (0.55) BDKRB1ALDH1A1KCNH2HPGDHSD17B10
SCHEMBL3275296 0.89 SMN1; SMN2 (0.66) BDKRB1SMN1; SMN2ALDH1A1KCNH2CYP1A2
SCHEMBL3275545 0.89 BDKRB1 (0.57) BDKRB1ALDH1A1KCNH2HPGD
SCHEMBL3278506 0.89 BDKRB1 (0.57) BDKRB1ALDH1A1KCNH2HPGD
SCHEMBL3274439 0.88 NPC1 (0.47) BDKRB1SMN1; SMN2KCNH2
SCHEMBL3280746 0.88 SMN1; SMN2 (0.47) BDKRB1SMN1; SMN2ALDH1A1KCNH2CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2076491-B1 NEW BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS RICHTER GEDEON NYRT (HU) 2013-07-17 EP claimed
US-8481527-B2 Benzamide derivatives as bradykinin antagonists RICHTER GEDEON NYRT. (HU) 2013-07-09 US claimed
US-20100087423-A1 NEW BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS RICHTER GEDEON NYRT. (HU) 2010-04-08 US claimed
EP-2076491-A1 NEW BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS Richter Gedeon NYRT (HU) 2009-07-08 EP claimed
WO-2008068540-A1 NEW BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS RICHTER GEDEON NYRT. (HU) 2008-06-12 WO claimed
EP-2076491-B1 NEW BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS RICHTER GEDEON NYRT (HU) 2013-07-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087423-A1 NEW BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS BDKRB1, BDKRB2, HRH1 BDKRB1 1/4885SMN1; SMN2 4508/4885THRA 1781/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.